Research programme: gene therapies - Novo Nordisk
Latest Information Update: 29 Oct 2025
At a glance
- Originator bluebird bio; Novo Nordisk
- Developer Genetix Biotherapeutics; Novo Nordisk
- Class Blood coagulation factors; Gene therapies
- Mechanism of Action Factor VIII modulators; Gene transference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haemophilia A
Most Recent Events
- 29 Oct 2025 No development reported - Preclinical for Haemophilia A in Denmark (Parenteral) (Genetix Biotherapeutics and Novo Nordisk pipeline, October 2025)
- 29 Oct 2025 No development reported - Preclinical for Haemophilia A in USA (Parenteral) (Genetix Biotherapeutics and Novo Nordisk pipeline, October 2025)
- 18 Sep 2025 bluebird bio is now called Genetix Biotherapeutics